LOS ANGELES, Sep. 6 /PRNewswire-FirstCall/ -- Signalife, Inc. (Amex: SGN) has announced that the legendary Earvin "Magic" Johnson has joined Athletes for Life ("AFL") to endorse ambulatory heart testing with AFL's flagship choice, Signalife's Fidelity 100 and its related products and technologies. One of the greatest basketball superstars of all time, Mr. Johnson has also had unparalleled business successes after winning multiple championships from college to the Los Angeles Lakers to the Olympic Gold Medal. "Magic" has joined the likes of Jim Brown, Reggie Bush, Joe Theisman, Willie Gault, Thomas "Hitman" Hearns and countless other current and former professional athletes in fighting cardiovascular disease -- the number one killer in the United States. They wish to fight it by prevention -- not by watching their teammates and friends die. This is a staple of AFL and Signalife.
Signalife, Inc. President Dr. Lowell Harmison -- an AFL member, a former collegiate running back, and former Principal Deputy of the United States DHHS -- commented that "I am personally overjoyed that Earvin "Magic" Johnson -- as he is historically famous for -- has shown the field of vision to understand that something is wrong when we have millions of people being deprived of the ability to obtain a complete 12-lead ECG signal of their own heart when they are moving (ambulatory). The heart is a muscle. To be unable to properly test that muscle when it is "at work" is -- we believe -- the cause of significant failures in detection of disease. This is an undisputed fact."
"To have somebody with Mr. Johnson's background and achievement become a part of this cause is very gratifying to me, to all of the 50+ founding members of Athletes for Life and to the Board controlling the only device capable of capturing the data, seeing the signals and leveling the playing field -- Signalife's Fidelity 100," added Dr. Harmison.
Willie Gault, the co-founder of Athletes for Life, stated that "As we continue to expand the reach of sponsorship in favor of the utilization of Signalife's technologies to all portions of our society, the cost of cardiovascular disease -- to the government, to society and to individuals of all income levels -- will change dramatically. To have my friend "Magic" Johnson as a part of the team is something I personally appreciate and is a development that will significantly support and assist our efforts on assuring that this is an endeavor that reaches all portions of our society. This is a very exciting day for me."
Two years ago, Mr. Gault experienced the horror of having three close friends -- former NFL superstars -- die of sudden heart attack at very young ages and while having clean bills of health from their physicians. The proliferation of the Fidelity 100 -- Signalife's FDA approved heart device -- is intended to change the status quo where these tragic events repeatedly occur and where there is no resulting change in cardiovascular care. In the words of Mr. Gault: "The change is upon us now, and AFL will be there to assure it has the appropriate reach into all socio-economic portions of society."
Signalife, Inc. is a life sciences company focused on the monitoring and detection of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory setting.
Signalife is publicly traded on the American Stock Exchange under the symbol SGN. The website for the company is http://www.Signalife.com. Clear Data. Trusted Results.
Caution Regarding Forward-Looking Statements
Statements in this release that are not strictly historical are "forward- looking" statements. Forward-looking statements involve known and unknown risks, which may cause Signalife's actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Signalife's technology, failure to obtain federal or state regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife's technology, inability to obtain physician, patient or insurance acceptance of for heart monitoring and other biomedical incorporating Signalife's technology, and the unavailability of financing to complete management's plans and objectives, including the development of heart monitoring and other biomedical incorporating Signalife's technology. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife's filings with the Securities and Exchange Commission.
|SOURCE Signalife, Inc.|
Copyright©2007 PR Newswire.
All rights reserved